Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding ProgramWinter 2017 Special RFA, American Cancer Society Pilot Grants 

 

► MCW Cancer Center Pilot Funding Award Cycles

 

 

 

Spring 2016

Fall 2017

RFA Released

5/15/2016

11/15/2016 Click Here for RFA and Forms

LOI Due

6/1/2016

12/1/2016

Application Due

7/15/2016

1/15/2017

Review Committees

8/21 - 9/4/2016

2/13 – 2/25/2017

Funding Decision

First Thursday of  October

First Thursday of April

Earliest Start Date

1/1/2017

6/1/201

 

Spring 2017

Fall 2018

RFA Released

5/15/2017

11/15/2017

LOI Due

6/12017

12/1/2017

Application Due

7/14/2017

1/15/2018

Review Committees

8/21 - 9/1/2017

2/15 – 2/26/2018

Funding Decision

First Thursday of October

First Thursday of April

Earliest Start Date

1/1/2018

6/1/2018

 

National Cancer Institute (NCI)

Open AllClose All
  Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) (Deadline: 5/7/17)

Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)

This funding opportunity announcement (FOA) seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multi-disease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions.

The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension.

Applications due May 7, 2017

  Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01) (Deadline: 5/9/17)

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials.

The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.

Applications due May 9, 2017

  Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3) (Deadline: 5/9/17)

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)

This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.

The scientific scope of this FOA includes:

  • Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support;
  • Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials.

A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development and optimization of QI tools and methods chosen for study by the investigating team, while the UH3 phase is for the validation of the tools/methods developed in the UG3 phase. The UG3 phase can be no more than 2 years in duration, and the total project cannot exceed 5 years. At completion, UG3 projects will be reviewed by program staff. Those that have met their milestones may be administratively considered by NCI program staff for transition to the UH3 validation phase.

Applications due May 9, 2017

  Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01) (Deadline: 5/22/17)

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01)

The overarching objectives of this initiative are to understand the etiologic factors and the underlying mechanisms responsible for chronic liver diseases and documented cancer disparities among racial/ethnic minority and socioeconomically disadvantaged populations in the US. For the purpose of this initiative the focus is on the causes for increase in both the incidence and mortality rates of chronic liver disease and cancer among the health disparities populations.

Many potential individual, contextual and structural factors influence health disparities; therefore, this FOA invites applications that include multidisciplinary research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Since the causes of health disparities are complex, applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and HCC. In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate.

Applications due May 22, 2017

  Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21) (Deadline: 5/22/17)

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21)

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. This FOA utilizes the Research Project Grant (R21) mechanism, and is suitable for early phase, pilot, or exploratory/developmental projects. Investigators who are interested in proposing larger scale, later phase projects based upon substantial preliminary data should submit applications to the companion FOA PAR-17-151 of identical scientific scope which uses the NIH (R01) grant mechanism.

Many potential individual, contextual and structural factors influence health disparities; therefore, this FOA invites applications that include multidisciplinary exploratory research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Since the causes of health disparities are complex, applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and HCC. In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate.

Applications due May 22, 2017

  U.S. Tobacco Control Policies to Reduce Health Disparities (R01) (Deadline: 6/5/17)

U.S. Tobacco Control Policies to Reduce Health Disparities (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment).

Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research.

Applications due May 24, 2017

  U.S. Tobacco Control Policies to Reduce Health Disparities (R21) (Deadline: 5/24/17)

U.S. Tobacco Control Policies to Reduce Health Disparities (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment).

Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research.

Applications due May 24, 2017

  Cancer Research Education Grants Program - Courses for Skills Development (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Courses for Skills Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Cancer Research Education Grants Program - Curriculum or Methods Development (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Curriculum or Methods Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Research Experiences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01) (Deadline: 5/26/17)

Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01)

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the individual, team, healthcare system or community setting levels. Appropriate applications for this FOA should propose to intervene at one or more levels, and must measure outcomes at three or more levels, while accounting for interactions that occur between levels.

Applications due May 26, 2017

  Perception and Cognition Research to Inform Cancer Image Interpretation (R01) (Deadline: 5/30/17)

Perception and Cognition Research to Inform Cancer Image Interpretation (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Applications due May 30, 2017

  Perception and Cognition Research to Inform Cancer Image Interpretation (R21) (Deadline: 5/30/17)

Perception and Cognition Research to Inform Cancer Image Interpretation (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application needs not have extensive background material or preliminary information.

Applications due May 30, 2017

  Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp) (Deadline: 6/1/17)

Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp)

The National Cancer Institute (NCI) hereby notifies Program Director(s)/Principal Investigator(s) holding eligible awards (as specified in this FOA) that funds are available for administrative supplements to prepare and deposit individual-level data from cancer epidemiology studies into NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.

Applications due June 1, 2017

  Serious Adverse Drug Reaction Research (R01) (Deadline: 6/1/2017)

Serious Adverse Drug Reaction Research (R01)

The objective of this FOA is to encourage research projects addressing current gaps in our knowledge of serious ADRs, particularly those that are idiosyncratic. These gaps exist along the translational spectrum. Potential areas of study include, but are not limited to, basic research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the development of therapies and interventions to treat and prevent serious ADRs. Within the broad range of objectives outlined above, applications must be within scope of the participating Institutes/Centers delineated below. Potential applicants are encouraged to contact IC scientific representatives for further information.

NCI welcomes applications for pre-clinical, translational, and clinical research on: mechanisms underlying serious ADRs, including organ toxicities and immune-related ADRs, resulting from anti-cancer therapies; discovery and integration of informative biomarkers for prediction, early detection, or monitoring of ADRs; development and validation of clinical assays or tools for measuring these ADR markers; and development of interventions for alleviation of severe and/or chronic ADRs in cancer patients. Other areas of NCI interest include: development, testing, interpretation and the use of patient-reported outcome (PRO) measures to capture symptomatic toxicities, such as fatigue, nausea and neuropathy, in cancer patients; and epidemiologic surveillance over time of serious ADRs.

Applications due June 1, 2017

  Serious Adverse Drug Reaction Research (R21) (Deadline: 6/1/2017)

Serious Adverse Drug Reaction Research (R21)

The objective of this FOA is to encourage exploratory/developmental research projects addressing current gaps in our knowledge of serious ADRs, particularly those that are idiosyncratic. Exploratory and developmental research projects provide support for the early and conceptual stages of a project. These studies may involve considerable risk but may lead to a breakthrough in serious adverse drug reaction research, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on the field. The gaps to be addressed in the FOA exist along the translational spectrum. Potential areas of study include, but are not limited to, basic exploratory/developmental research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the exploratory development of therapies and interventions to treat and prevent serious ADRs. Within the broad range of objectives outlined above, applications must be within scope of the participating Institutes/Centers delineated below. Potential applicants are encouraged to contact IC scientific representatives for further information.

NCI welcomes applications for pre-clinical, translational, and clinical research on: mechanisms underlying serious ADRs, including organ toxicities and immune-related ADRs, resulting from anti-cancer therapies; discovery and integration of informative biomarkers for prediction, early detection, or monitoring of ADRs; development and validation of clinical assays or tools for measuring these ADR markers; and development of interventions for alleviation of severe and/or chronic ADRs in cancer patients. Other areas of NCI interest include: development, testing, interpretation and the use of patient-reported outcome (PRO) measures to capture symptomatic toxicities, such as fatigue, nausea and neuropathy, in cancer patients; and epidemiologic surveillance over time of serious ADRs.

Applications due June 1, 2017

  Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp) (Deadline: 6/1/17)

Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for supplemental funding to eligible NCI awards so that involved personnel (awardees) can advance their efforts to gain needed knowledge on rare cancers. The goal is to support population-based, hypothesis-testing studies that will increase our understanding of the etiology or post-diagnosis outcomes of rare cancers.

Applications due June 1, 2017

  Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp) (Deadline: 6/1/17)

Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp)

The National Cancer Institute (NCI) announces an opportunity for awardees holding eligible NCI-funded awards to request administrative supplement funding to support augmented efforts to refine automated methodologies to obtain more accurate and reliable lifetime residential history data and linkages that would enhance cancer research.

Applications due June 1, 2017

  Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01) (Deadline: 6/5/17)

Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem. The proposed systems may include molecular diagnosis, molecular imaging or related research resources.

Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others:

(a) current commercially supported systems,

(b) next-generation systems,

(c) quality assurance and quality control,

(d) validation and correlation studies,

(e) quantitative imaging, and

(f) related research resources.

Because applications should be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. In addition, innovation may be considered as delivery of a new capability to end users. The partnership on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem.

This FOA will support clinical trials that test functionality, optimize, and validate the performance of the proposed translational work. This FOA does not intend to support either actual commercial production or basic research projects that do not emphasize translation.

Applications due June 5, 2017

  Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01) (Deadline: 6/5/17)

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

This FOA will not support phase III clinical trials.

Applications due June 5, 2017

  Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01) (Deadline: 6/5/17)

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Applications due June 5, 2017

  Early-Life Factors and Cancer Development Later in Life (R01) (Deadline: 6/5/17)

Early-Life Factors and Cancer Development Later in Life (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 5, 2017

  Mechanisms of Alcohol-associated Cancers (R01) (Deadline: 6/5/17)

Mechanisms of Alcohol-associated Cancers (R01)

This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

Applications due June 5, 2017

  Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) (Deadline: 6/5/17)

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01)

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival.

Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Applications due June 5, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01) (Deadline: 6/5/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 5, 2017

  Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01) (Deadline: 6/7/17)

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.

The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Applications due June 7, 2017

  Alliance of Glycobiologists for Cancer Research: Translational Tumor Glycomics Laboratories (U01) (Deadline: 6/8/17)

Alliance of Glycobiologists for Cancer Research: Translational Tumor Glycomics Laboratories (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the “Alliance of Glycobiologists for Cancer Research” (http://glycomics.cancer.gov). Through this FOA, the NCI encourages research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins.

In their applications, applicants are encouraged to address the ability of these biomarker candidates to accurately distinguish individuals with cancer from those without. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects. All investigators with appropriate expertise and capabilities, irrespective of any prior association with this Alliance, are encouraged to consider applying to this FOA.

Applications are due June 8, 2017

  Alliance of Glycobiologists for Cancer Research: Biological Tumor Glycomics Laboratories (U01) (Deadline: 6/8/17)

Alliance of Glycobiologists for Cancer Research: Biological Tumor Glycomics Laboratories (U01)

This Funding Opportunity Announcement (FOA) is intended to support research applications that are focused on mechanisms that mediate alterations in glycosylation during oncogenesis. The goal of this FOA is to advance our knowledge of altered glycosylation or other modifications in carbohydrate structure in cancer to determine whether it is the cause or the result of neoplastic transformation.

Because the research is intended to examine the biology of how modifications in carbohydrate structure influence malignancy during different stages of the disease, this FOA will support research teams that have complementary expertise in glycobiology and cancer biology to focus on mechanisms that mediate alterations in glycosylation during oncogenesis.

Applications due June 8, 2017

  Paul Calabresi Career Development Award for Clinical Oncology (K12) (Deadline: 6/15/17)

Paul Calabresi Career Development Award for Clinical Oncology (K12)

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).     

Applications due June 15, 2017

  Early-Life Factors and Cancer Development Later in Life (R03) (Deadline: 6/16/17)

Early-Life Factors and Cancer Development Later in Life (R03)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 16, 2017

  Early-Life Factors and Cancer Development Later in Life (R21) (Deadline: 6/16/17)

Early-Life Factors and Cancer Development Later in Life (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 16, 2017

  Mechanisms of Alcohol-associated Cancers (R21) (Deadline: 6/16/17)

Mechanisms of Alcohol-associated Cancers (R21)

This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

Applications due June 16, 2017

  Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) (Deadline: 6/16/17)

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Applications due June 16, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21) (Deadline: 6/16/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 16, 2017

  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01) (Deadline: 6/28/17)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Applications due June 28, 2017

  Research Answers to NCI's Provocative Questions (R01) (Deadline: 6/28/17)

Research Answers to NCI's Provocative Questions (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 28, 2017

  Research Answers to NCI's Provocative Questions (R21) (Deadline: 6/28/17)

Research Answers to NCI's Provocative Questions (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported P01 Awards to Include Research on the NCI's Provocative Questions (P01) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P01 Program Projects. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P01 award.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported P50 Awards to Include Research on the NCI's Provocative Questions (P50) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P50 Specialized Centers. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.

Applications due June 28, 2017

  Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01) (Deadline: 6/28/17)

Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)

This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported U01 Awards to Include Research on the NCI's Provocative Questions (U01) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)

This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research project awards. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.

Applications due June 28, 2017

  Cooperative Agreement to Develop Targeted Agents for Use With Systemic Agents Plus Radiotherapy (U01) (Deadline: 7/14/17)

Cooperative Agreement to Develop Targeted Agents for Use With Systemic Agents Plus Radiotherapy (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

Applications due July 14, 2017

  Inter-organelle Communication in Cancer (R01) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.  

Applications due August 16, 2017

  Inter-organelle Communication in Cancer (R21) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

Applications due August 16, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Prostate Cancer Foundation (PCF) (Deadline: 4/24/17)

Prostate Cancer Foundation (PCF)

The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.

PCF Challenge Awards:

  • Team science awards are composed of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below).
  • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years.
  • Provide up to a total of $1 million per team.
  • Cover only direct research costs and travel to the Annual PCF Scientific Retreat.

Research proposals in the following topic areas are preferred:

  • Immunotherapy for the treatment of metastatic, lethal prostate cancer.
  • Targeted radionuclide therapy for advanced prostate cancer.
  • New systemic treatments for metastatic, lethal prostate cancer including those targeting the currently `undruggable'.
  • First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
  • Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system and chemotherapy.
  • Correlative research around either clinical trials of novel agents or strategies or standard of care.
  • Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
  • Tumor microenvironment signaling related to cancer progression including the immune component.
  • New bioinformatics technologies for analysis of genomic data.

Applications due April 24, 2017

  Elsa U. Pardee Foundation (Deadline: 4/30/17)

Elsa U. Pardee Foundation

The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Applications due April 30, 2017

  LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation) (Deadline: 5/5/17 - by invitation only)

LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation)

LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and successful treatment of lung cancer. LUNGevity's mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of lung cancer, early intervention in the disease progression, and targeted therapeutics, including immuno-oncology. LUNGevity focuses on translational science.

LUNGevity's Career Development Awards for Translational Research program was created with one goal: to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research projects are restricted to translational lung cancer research, and the applicant must demonstrate the translational relevance of the research proposed. The CDAs are mentored awards; a mentoring plan will be part of the required submission.

High-risk, high-return proposals will receive equal consideration. Translational research includes epidemiology studies, and LUNGevity especially encourages clinical correlative studies. Proposed projects must make use of human biopsies or samples. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not. Translational research includes epidemiologic, clinical/correlative, or thoracic surgical research. The use of existing resources is encouraged, including libraries of compounds or probes, tissue or bio-specimen repositories, and other existing sets of tissue, blood, or images. It is strongly encouraged that those applying have direct and immediate access to the bio-specimens necessary to complete their research.

Applications due May 5, 2017 (by invitation only)

  Stand Up To Cancer - LUNGevity - American Lung Association Lung Cancer Interception Dream Team (Deadline: 5/12/17)

Stand Up To Cancer - LUNGevity - American Lung Association Lung Cancer Interception Dream Team

Submissions of ideas will be invited for a translational cancer research project that addresses critical problems in lung cancer and positively impacts patients in the near future, with the goal of advancing innovative approaches to prevent or intercept the disease-causing process, and making data available in a format amenable to open access analytics. Prioritized areas of interest include: research that accurately categorizes pre-malignant conditions according to risk of progression and that elucidates the underlying alterations that increase that risk; potential surrogate endpoints for clinical trials and regulatory approval; new tools for early detection and monitoring progression; the role of inflammation and immunosuppression in progression; investigation of therapeutic chemoprevention targets; or research targeted at generating sufficient knowledge to justify a clinical intervention to test novel hypotheses.

This proposed project is expected to benefit patients through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. Priority will be given to applications that are characterized by a diversity of team members, including and not limited to those from fields outside the traditional realms of biomedical research (e.g. physics, mathematics, engineering, health policy, and communications). Specific aims of the project may include basic research, translational studies, and population studies but the overall proposal must have a strong clinical research component. Proposals for this Dream Team research project must present plans indicating how the work will be translated into clinical application. The concepts will be evaluated on innovation, feasibility, opportunities for success and further development, including improved long-term outcomes for patients.

Through a partnership with leading health care research and innovation collaborative OptumLabs, each team will have the ability to conduct research using OptumLabs' proprietary database of de-identified claims and electronic health record data, analytic tools, and research support to pursue the proposed goals of the Dream Team. Appendix A provides more information on OptumLabs. Collaboration with OptumLabs is optional, and anticipated participation should be delineated as part of the research proposal narrative.

Applications due May 12, 2017

  Stand Up To Cancer - Lustgarten Foundation Pancreatic Cancer Interception Dream Team (Deadline: 6/26/17)

Stand Up To Cancer - Lustgarten Foundation Pancreatic Cancer Interception Dream Team

Submissions of ideas will be invited for a translational cancer research project that addresses critical problems in pancreatic cancer and positively impacts patients in the near future, with the goal of advancing innovative approaches to prevent or intercept the disease-causing process, and making data available in a format amenable to open access analytics. Prioritized areas of interest include both applied and fundamental research including: The discovery and implementation of innovative methods that effectively detects pancreatic cancer at an early and surgically curable stage; new tools for monitoring disease progression and therapeutic response, which could potentially serve as surrogate endpoints for clinical trials and regulatory approval; investigation of novel chemoprevention or immune prevention approaches; the development of risk prognostication methods for pre-invasive pancreatic neoplasms and other conditions that elucidates the molecular details underlying that increased risk; the understanding of immune suppression and inflammation mechanisms that promote pancreatic cancer and the design of methods to circumvent this; and more generally research targeted at generating sufficient knowledge to justify a clinical intervention to test novel hypotheses related to early detection and treatment of pancreatic cancer.

This proposed project is expected to benefit patients through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. Priority will be given to applications that are characterized by a diversity of team members, including those from fields outside the traditional realms of biomedical research (e.g. physics, mathematics, engineering, health policy, and communications). Specific aims of the project may include basic research, translational studies, and population studies but the overall proposal must have a strong clinical research component. Proposals for this Dream Team research project must present plans indicating how the work will be translated into clinical application. The concepts will be evaluated on innovation, feasibility, opportunities for success and further development, including improved long-term outcomes for patients.

Applications due June 26, 2017

  Educational Grants (Bayer AG; Bayer USA Foundation) (Deadlines: 8/8/17 for Oncology; 10/1/17 for Generic Education)

Educational Grants (Bayer AG; Bayer USA Foundation)

The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests:

  1. Healthcare professional education
  2. Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.)

Areas of Support:

  • Dermatology
  • Radiology
  • Hematology-Hemophilia
  • General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
  • Neurology
  • Women's Health

Oncology:

  • Advanced Prostate Cancer
  • Colorectal Cancer
  • Gastrointestinal Stromal Tumor
  • Hepatocellular Carcinoma
  • Thyroid Cancer

Applications due August 8, 2017 (Oncology); October 1, 2017 (Generic Education)

  St Baldrick’s Foundation (SBF) (Deadline: 8/31/17)

St Baldrick’s Foundation (SBF)

These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.

Applications due August 31, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

MCW – Cardiovascular Center (CVC) (Deadline: 5/1/17)

MCW – Cardiovascular Center (CVC) (PDF)

As many of you know, the Cardiovascular Center (CVC) was visited last May by an External Scientific Advisory Board (ESAB) composed of international experts in cardiovascular research who provided the CVC with key recommendations in early Fall to further the CVC’s mission and vision. This report, along with feedback from our Internal Scientific Advisory Board (ISAB), institutional leadership, and from our Town Hall Meetings and informal discussions, has resulted in the following exciting funding opportunities that are made possible by the CVC’s parent award from the Advancing a Healthier Wisconsin Endowment Research and Education Program (AHW-REP), philanthropic contributions to the CVC, collaborative efforts with MCW’s Cancer Center, and the Dean’s institutional funds.

The CVC is pleased to offer funding to CVC members for multiple “Signature Program Pre-PPG” awards including two “Pre-PPG Awards” with an emphasis on Cardio-Oncology in collaboration MCW Cancer Center. The primary goal of the Pre-PPG awards is to elevate our Signature Programs to the next medal level (from Bronze to Silver or Silver to Gold) by investing in team science that will produce program project grants or similar extramural awards. This new programmatic focus is a priority for the CVC as we shift from our exclusive support of smaller pilot grants awarded to individual PIs. Notwithstanding, we are offering two pilot grants, which are supported by the Dr. Michael Keelan, Jr., MD, Research Foundation, for eligible junior or mid-career investigators without current R01-equivalent funding. We especially encourage applications from clinical faculty for this funding mechanism.

Detailed application materials will be distributed soon.

CVC Members: Please RSVP and attend the CVC’s Town Hall Meeting next Wednesday, February 22, from 12-1:30 p.m. in H4950 as we will be discussing and answering questions about these funding opportunities.

Applications due May 1, 2017

Other

Open AllClose All
  PCORI Funding Announcement: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes (Deadline: 5/17/17)

PCORI Funding Announcement: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities.

Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

For this solicitation, applicants are not required to demonstrate that patients and other stakeholders are already engaged as research team members at the time an application is submitted. However, applicants should outline how patients and other stakeholders will participate as partners in various phases of the proposed research, once awarded. Applicants should describe their plan to form a Study Advisory Committee (SAC)[1] or other appropriate engagement body, to ensure that a broad spectrum of patients and other stakeholders advise and assist the research team with refining the study questions, outcomes, and protocols. These patients and other stakeholders must include national or regional organizations that represent—at a minimum—patients, caregivers, clinicians, policy makers, and other healthcare system stakeholders. Additional representation may be recommended in collaboration with PCORI, including individual patients with lived experience and other relevant stakeholders, such as scientific and methodological experts.

Applications due May 17, 2017

  ‘A’ Award - Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 5/22/17)

‘A’ Award - Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

In line with its mission, ALSF offers the 'A' Award as a four-year grant designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A career development plan should be outlined. A mentor is optional but is strongly encouraged at least in the initial stages of the project (the first 1-2 years of support). A career development plan must be included.

'A' Award Program Goals:

  • To encourage the best and brightest early career independent researchers to build lifelong careers and become leaders in the field of pediatric cancer research.
  • To advance research that will lead to new treatments and cures impacting children with cancer.

Application due May 22, 2017

  Investigator's Award in Clinical Translation of Gene Therapy for Cancer: Investigator's Award in Clinical Translation of Cell and Gene Therapy for Cancer (ACGT) (Deadline 5/22/17)

Investigator's Award in Clinical Translation of Gene Therapy for Cancer: Investigator's Award in Clinical Translation of Cell and Gene Therapy for Cancer (ACGT)

ACGT funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards to support research in clinical translation of cell and gene therapy for cancer.

ACGT RESEARCH OBJECTIVES

A number of cell and gene therapy approaches for cancer have been shown to be efficacious and safe in laboratory animal models in the recent years, but their translation into clinical trials has been hindered by a lack of resources. Recognizing this critical need, ACGT is accepting grant applications to produce and release-testing of the clinical trial agents under cGMP, conduct the necessary pre-clinical pharmacological and toxicological studies in appropriate animal models, and/or conducting the clinical translational trials in patients in support of an Investigative New Drug (IND) application to the FDA. While the unambiguous demonstration of PRECLINICAL TREATMENT EFFICACY DATA IN TUMOR-BEARING ANIMALS in cancer treatment by cell and gene therapy is a pre-requisite, entering into the clinical trial during the funding period is also a requirement. Applications that do not include this specific aim will be deemed unresponsive to the RFA.

Applications due May 22, 2017

  Medical Research Grants: Reach Awards - Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 5/22/17)

Medical Research Grants: Reach Awards - Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

The purpose of the Reach Grant is to advance ALSF's mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late translational studies. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.

Proposals must fall within the scope of ALSF's mission, focused on childhood cancers. Proposals with a sole/primary focus on patients >21 years of age will not be considered.

Proposals will be evaluated based on their late-translational potential. Thus, screening projects, discovery projects, and early-translational projects are more appropriate for other ALSF funding mechanisms.

Preliminary data are required. The proposal must be hypothesis driven and demonstrate feasibility.

Explicit timeline and time-based deliverables for the proposed studies must be presented.

A plan for clinical implementation of the concept and an overall clinical development plan for the therapeutic approach must be included with a projected timeline for completing the trial. (Note: This grant does not fund clinical trials.)

Application due May 22, 2017

  Breast Cancer Alliance (BCA) (Deadline: 7/22/17)

Breast Cancer Alliance (BCA)

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, the BCA invests in innovative research, breast surgery fellowships, regional education, dignified support and screening for the uninsured and underserved.

The BCA offers the Young Investigator Grant to encourage a commitment to breast cancer research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

Applications due July 22, 2017

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

Top